Our Vision is Your Vision
We cherish the trust you have placed in us and are committed to provide patients the latest advances in medical research, world-class doctors, state of the art technology, and superbly trained staff. We promise to provide the best possible eyecare to protect, to preserve, and to enhance your visual needs.
Featured Services
Am I at Risk for Glaucoma?
Glaucoma is an eye disease that generally progresses slowly. In fact, one-half of glaucoma patients are not aware they have the disease. It is estimated that two million Americans may have Glaucoma. In order to maintain healthy vision, annual eye exams are recommended. Below are risk factors for Glaucoma:
- Age, over 65
- Age, over 75*
- African-American descent (or any other dark skinned race) *
- Family with glaucoma – A parent
- Family with Glaucoma- Brother or sister*
- Myopia (near-sightedness) of a significant degree
- History of previous eye injury or surgery
- Use of steroids (pills, nose spray inhalants, or eye drops) for more than a month
- Complete eye examination – More than 2 years ago
- Complete eye examination – More than 5 years ago*
If you have more than two of these risk factors, or any of the risk factors with an asterisk, consider yourself at moderate or high risk for glaucoma.
Valeda Light Therapy
Valeda Light Treatment is the first FDA‑cleared photobiomodulation therapy designed to improve retinal function and support long‑term eye health. Using gentle, non‑invasive wavelengths of light, Valeda helps enhance cellular energy, reduce inflammation, and promote healthier retinal activity — all without discomfort or downtime.
This innovative treatment is especially beneficial for patients experiencing early functional changes in the retina, including those with age‑related concerns. Many patients report improvements in visual clarity, contrast sensitivity, and overall comfort after completing a treatment series.
Valeda therapy is:
- Non-invasive and pain free
- Completed in a series of quick in-office sessions
- Designed to support retinal metabolism and cellular repair
- Backed by clinical research in photobiomodulation
Is it Ocular Surface Disorder or Dry Eye?
At Specialty Eyecarè Centre it is relatively common for us see patients who have been suffering for several years with dry eye symptoms but like many adults, they have attributed these symptoms to environmental factors, medications, extended computer use, etc. and have never sought any formal or structured treatment plan. In the case of our patients who suffer from glaucoma, treatment of dry eye is extremely important not only for the comfort of the patient, but for the long term health of the surface of the eye. So we have to manage both conditions, sometimes simultaneously, sometimes one at a time.
While you may not think you suffer from dry eye or ocular surface disorder, it is very possible that it is affecting your everyday activities. The exact cause is still being researched; however it can be caused by a number of factors. Dry eye can result from a decrease in tear production and/or an increase in tear film evaporation.
Advanced Cataract Surgery
Nearly everyone will develop cataracts at some point in life. Typically, the symptoms will begin after one turns 55. Fortunately, cataract surgery has progressed to be not only the most performed surgery in the US, but one of the safest. Now those with cataracts have the option to have clear vision after cataract surgery with the use of premium lenses! We are proud to be the first in the region to offer ORA – Optiwave Refractive Analysis during cataract surgery, providing the most accurate cataract surgery results possible!
Our Research
One of the unique features Specialty Eyecarè Centre is especially proud of is our commitment to being involved with the development of innovative and cutting edge medical advances. This has not been a new phase in the growth of Specialty Eyecarè Centre, but rather, a core part of the mission of the practice for over 25 years.
We encourage you to learn more about our ongoing research and studies.
